“It’s the most promising medicine to cure COVID-19” – Russia says.
MOSCOW Russia (Efe) – Avifavir is the first antiviral drug to treat COVID-19 registered by the Russian Ministry of Health after showing “great effectiveness” during clinical trials, according to the Russian Fund for Direct Investment (FRID)
The drug is based on favipiravir, which had already shown success in Japan. The Russian product is “categorically contraindicated” for pregnant women.“Avifavir is the first antiviral drug registered in Russia to treat the coronavirus and perhaps the most promising medicine to cure COVID-19 worldwide,” said FRID Director-General Kiril Dmitriev, quoted in a FRID statement.
According to the Russian official, this drug was developed and clinically tested “in record time.” It allowed it to become the first medicine based on favipiravir -antiviral developed in Japan- registered worldwide. Favipiravir, a generic antiviral, had already shown efficacy at an early stage of the disease and is marketed in Japan to treat severe influenza cases.
Avifavir, according to FRID, has shown high effectiveness in affecting the reproduction mechanisms of the coronavirus. The FRID has acknowledged that the drug is “categorically contraindicated” for pregnant women and people in the process of family planning.
Also, the FRID noted that it would not be available initially in pharmacies and “will only be used in hospitals under medical observation”.
In mid-May, Dmitriev said that 60 percent of the 40 coronavirus patients who took favipiravir tested negative for the virus within five days and indicated that the treatment could cut recovery time in half. According to data from clinical trials, the drug has high efficacy against COVID-19. The final stage of Avifavir’s clinical trials, involving 330 patients, is underway.
Russia has the second-highest number of coronavirus cases after the United States. Currently, they are testing prototype vaccines in animals, while the fund has redirected resources to produce more tests locally.
This week, the World Health Organization temporarily halted clinical trials of hydroxychloroquine in patients with COVID-19, as higher death rates were detected in patients receiving the treatment. The decision, a cautionary measure that could be reviewed, followed the publication in the medical journal The Lancet of a study indicating higher death rates.
Favipiravir is also being tested in India by Glenmark Pharmaceuticals Ltd while WHO-sponsored clinical trials are checking the antiviral drug remdesivir (commonly used against Ebola), a combination of lopinavir and ritonavir (widely used for HIV carriers), and interferon beta, a standard treatment for multiple sclerosis, in patients.
more recommended stories
Hurricane Rick makes landfall on Mexico’s Pacific coast
MEXICO CITY, October 25, 2021, (Reuters).
Prepare a delicious pumpkin syrup dessert for the Hanal Pixán Altar
MÉRIDA, Yucatán, (October 25, 2021).- On.
Mexican Sergio “Checo” Perez finished third at the US Grand Prix in Austin, Texas
F1: Perez endures ‘toughest race’ without.
Cyclists demonstrate using life jackets in Paseo de Montejo to demand road safety
The mobilization has the objective of.
International company Accenture will settle in Tekax, Yucatán
Accenture is a global operations, technology.
Over forced labor allegations, U.S. blocks imports of tomatoes from Mexican farms
WASHINGTON/MEXICO CITY, October 25, 2021 (Reuters).
Moderna says its COVID-19 vaccine protective, safe in young children
October 25, 2021 (Reuters) – Moderna.
Mexicans prepare “Day of the Dead” altars (VIDEO)
This tradition honors the dead Location:.
Hurricane Rick makes landfall on Michoacan’s coast
MEXICO CITY (Reuters) – The eye.
Bus accident on the Felipe Carrillo Puerto-Chetumal highway leaves 3 dead and several injured
Chetumal, Quintana Roo, (October 25, 2021).-.